Drugs / Iodophor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT03805542 | Aug 2019 → Aug 2020 | urolithiasis | Tongji Hospital | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03140423 Comparator | May 2017 → Nov 2023 | staphylococcus aureus infection | Harvard Pilgrim Health Care | Completed | No outcome recorded |
| Phase 4 | NCT00739583 Comparator | Aug 2008 → Aug 2009 | osteoarthritis, hip | Johns Hopkins University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iodophor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00739583 ↗ |
| Known as | povidone iodine | “Iodophor, also known as povidone iodine, is composed of iodine and polyol ether surfactants.” NCT03805542 ↗1“topical intranasal iodophor (10% povidone-iodine nasal swabs)” NCT03140423 ↗ |
| Route | Topical | “The area will be painted with the solution.” NCT00739583 ↗ |